Crucell Signs Commercial License Agreement with SingVax for Vaccines against Japanese Encephalitis

24-Mar-2005

Crucell N.V. announced the signing of a commercial PER.C6® license agreement with Singapore-based company SingVax Pte Ltd for the development and commercialisation of new vaccines against Japanese encephalitis. Under the agreement, SingVax will focus on the development and commercialisation of a Japanese encephalitis vaccine for the endemic population as well as for travellers to the Asia Pacific region.

Crucell will receive upfront, annual and milestone payments under the agreement, as well as royalties on product sales. In addition, Crucell will have a preferred position to negotiate marketing rights outside the Asia Pacific Region with respect to a traveller's vaccine that may be developed under the agreement in case SingVax make such a product available for licensing. Further details of the agreement were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances